Innovent Starts China Trial of Dual Agonist Obesity Treatment

Suzhou Innovent Bio has dosed the first person in a China Phase II trial of  a dual agonist treatment for obesity. IBI362 is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) that features once-weekly dosing. Innovent acquired China rights to the candidate from Lilly, its global partner. In 2015, the two companies signed a $1 billion deal for Innovent's PD-1 along with a two-way partnership of other assets. The trial will evaluate the change from baseline body weight at week 24. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.